Last-Chance cell therapy for blood cancer patients when standard product fails
NCT ID NCT07346105
First seen Jan 26, 2026 · Last updated May 20, 2026 · Updated 17 times
Summary
This program gives patients with blood cancers like leukemia or myelodysplastic syndrome access to Orca-T, a cell therapy, when the commercial version made for them doesn't meet quality standards. The goal is to provide treatment when no other option is available. Participants are monitored for serious side effects for one year after the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.